



Citation: 2021 BCSECCOM 351

Cease Trade Order

**Rakesh Malhotra
Graham Simmonds
(each referred to separately as the Insider)**

And

**Aion Therapeutic Inc.
Section 164 of the *Securities Act*, R.S.B.C. 1996, c. 418**

- ¶ 1 Aion Therapeutic Inc. is a reporting issuer and has not filed:
1. annual audited financial statements for the year ended April 30, 2021, as required under Part 4 of National Instrument 51-102 *Continuous Disclosure Obligations* (NI 51-102), and
 2. a Form 51-102F1 *Management's Discussion and Analysis* for the period ended April 30, 2021, as required under Part 5 of NI 51-102,
- (the required records).
- ¶ 2 The Insider may have knowledge of, or access to, a material fact or material change regarding Aion Therapeutic that has not been generally disclosed.
- ¶ 3 Aion Therapeutic has agreed to file, immediately after this order is granted, the Notice of Default and, if applicable, Default Status Reports, set out in National Policy 12-203 *Management Cease Trade Orders*.
- ¶ 4 Under section 164(1) of the Act, the Executive Director orders that all trading by the Insider in the securities of Aion Therapeutic cease until:
1. Aion Therapeutic files the required records, completed in accordance with the Act and rules, and
 2. the Executive Director revokes this order.
- ¶ 5 August 31, 2021

Anita Cyr, CPA, CA
Manager, Financial Reporting
Corporate Finance